Literature DB >> 27364949

Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme.

Wenqian Chen1, Cathy Lu2, Christina Hirota3, Marietta Iacucci3, Subrata Ghosh3, Xianyong Gui4,5.   

Abstract

BACKGROUND: The simplistically and ambiguously termed 'fibrostenosis' of bowel is a hallmark of severe Crohn's disease [CD] and a major contributor to medical treatment failure. Non-invasive imaging assessment and novel medical therapy targeting this condition are under investigation, which particularly requires a better understanding of the underlying histological basis.
METHODS: We analysed 48 patients with stricturing Crohn's ileitis or/and colitis that required surgical resection. The most representative sections of the fibrostenotic, non-stenotic and uninvolved regions were reviewed for histological analysis. For each layer of bowel wall (mucosa including muscularis mucosae [MU], submucosa [SM], muscularis propria [MP], subserosal adventitia [SS]), histological abnormalities were evaluated individually, including active and chronic inflammation, fibrosis, smooth muscle hyperplasia or hypertrophy, neuronal hypertrophy and adipocyte proliferation. A novel semiquantitative histological grading scheme was created.
RESULTS: The most significant histopathological features characterizing the stricturing intestines were smooth muscle hyperplasia of SM, hypertrophy of MP and chronic inflammation. The muscular alteration was predominant in all layers. The overall muscular hyperplasia/hypertrophy was positively correlated with chronic inflammation and negatively correlated with fibrosis, whereas SM muscular hyperplasia was also associated with MU active inflammation. Similar changes, to a lesser extent, occurred in the adjacent non-stenotic inflamed bowel as well.
CONCLUSIONS: In CD-associated 'fibrostenosis', it is the smooth muscle hyperplasia/hypertrophy that contributes most to the stricturing phenotype, whereas fibrosis is less significant. The 'inflammation-smooth muscle hyperplasia axis' may be the most important in the pathogenesis of Crohn's strictures.
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; fibrosis; fibrostenosis; muscular hypertrophy; smooth muscle hyperplasia; stricture

Mesh:

Year:  2016        PMID: 27364949     DOI: 10.1093/ecco-jcc/jjw126

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  33 in total

Review 1.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

2.  The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine.

Authors:  Anna Bin; Valentina Caputi; Michela Bistoletti; Monica Montopoli; Rocchina Colucci; Luca Antonioli; Sara De Martin; Ignazio Castagliuolo; Genny Orso; Cristina Giaroni; Patrizia Debetto; Maria Cecilia Giron
Journal:  Purinergic Signal       Date:  2018-09-29       Impact factor: 3.765

Review 3.  Immunological roles of intestinal mesenchymal cells.

Authors:  Robert J Nibbs; Kathy D McCoy; Allan Mcl Mowat; Carolyn A Thomson
Journal:  Immunology       Date:  2020-04-20       Impact factor: 7.397

4.  Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

Authors:  Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Satya Kurada; Noam Harpaz; Paula Borralho; Reetesh K Pai; Rish K Pai; Robert Odze; Roger Feakins; Claire E Parker; Tran Nguyen; Vipul Jairath; Mark E Baker; David H Bruining; J G Fletcher; Brian G Feagan; Florian Rieder
Journal:  Gastroenterology       Date:  2019-08-30       Impact factor: 22.682

5.  A Mouse Model of Intestinal Partial Obstruction.

Authors:  Se Eun Ha; Lai Wei; Brian G Jorgensen; Moon Young Lee; Paul J Park; Sandra M Poudrier; Seungil Ro
Journal:  J Vis Exp       Date:  2018-03-05       Impact factor: 1.355

6.  Toward Molecular Imaging of Intestinal Pathology.

Authors:  Mariane Le Fur; Iris Y Zhou; Onofrio Catalano; Peter Caravan
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

7.  Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.

Authors:  Geert D'Haens; Florian Rieder; Brian G Feagan; Peter D R Higgins; Julian Panés; Christian Maaser; Gerhard Rogler; Mark Löwenberg; Robbert van der Voort; Massimo Pinzani; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Gastroenterology       Date:  2019-06-27       Impact factor: 22.682

8.  Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease.

Authors:  Mathilde Wagner; Huaibin Mabel Ko; Manjil Chatterji; Cecilia Besa; Joana Torres; Xiaofei Zhang; Hinaben Panchal; Stefanie Hectors; Judy Cho; Jean-Frederic Colombel; Noam Harpaz; Bachir Taouli
Journal:  J Crohns Colitis       Date:  2018-05-25       Impact factor: 9.071

9.  Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis.

Authors:  Sophie Vieujean; Shurong Hu; Emeline Bequet; Catherine Salee; Charlotte Massot; Noëlla Bletard; Nicolas Pierre; Florence Quesada Calvo; Dominique Baiwir; Gabriel Mazzucchelli; Edwin De Pauw; Carla Coimbra Marques; Philippe Delvenne; Florian Rieder; Edouard Louis; Marie-Alice Meuwis
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

Review 10.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.